CUE HEALTH INC. Form 8-K (Aug. 3, 2023)

Summary

A Form 8-K current report of Cue Health Inc. to the U.S. Securities and Exchange Commission, dated August 3, 2023 and signed by Aasim Javed, Chief Financial Officer. Under Item 7.01, it states that on August 3, 2023 the company issued a press release announcing a new contract for approximately $28 million awarded by the Biomedical Advanced Research and Development Authority (BARDA). The contract is to develop an Influenza A/B, Respiratory Syncytial Virus, and COVID-19 molecular multiplex test for over-the-counter and point-of-care use. Item 8.01 repeats the award, and the press release is furnished as Exhibit 99.1.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 3, 2023

CUE HEALTH INC.

(Exact name of Registrant, as specified in its charter)

Delaware | 001-40590 | 27-1562193
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number)

Mailing address:

4980 Carroll Canyon Rd.

Suite 100

San Diego , CA 92121

(Address of principal executive

offices)

Registrant's telephone number, including area code: ( 858 ) 412-8151

Former name or address, if changed since last report: Not Applicable.

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.00001 per share | HLTH | Nasdaq Global Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On August 3, 2023, Cue Health Inc. (the "Company") issued a press release announcing that it has been awarded a new contract for approximately $28 million by the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services (“BARDA”), to develop an Influenza A/B, Respiratory Syncytial Virus (“RSV”), and COVID-19 molecular multiplex test for both over-the-counter (“OTC”) and point-of-care (“POC”) use.

A copy of the Company's press release dated August 3, 2023 announcing the Company's award from BARDA to develop an Influenza A/B, RSV, and COVID-19 molecular multiplex test is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.

The information contained in Item 7.01 of this Current Report on Form 8-K, including the information contained in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, and such information shall not be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended.

8.01 Other Events

On August 3, 2023, the Company was awarded a new contract for approximately $28 million by BARDA to develop an Influenza A/B, RSV, and COVID-19 molecular multiplex test for both OTC and POC use.

Item 9.01 Financial Statements and Exhibits.

Exhibit No. | Description
99.1 | Press release issued by Cue Health Inc. dated August 3, 2023
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cue Health Inc.

Date: August 3, 2023 | By: | /s/ Aasim Javed
Name: | Aasim Javed
Title: | Chief Financial Officer

3

File and source

File

SEC_CUE_8-K_filed2023-08-03_0001628945-23-000137.htm

Size

28,351 bytes

SHA-256

137bb798a0134e0addc56a1c45433c05cf3251c97af7ec507f87fc1165fba2e3

Our copy

SEC_CUE_8-K_filed2023-08-03_0001628945-23-000137.htm

Original

www.sec.gov